Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2011, Issue 3, 2011, Pages

  Karner, Charlotta ^a   Cates, Christopher J ^b  

^a BMJ   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; GLUCOCORTICOID; SCOPOLAMINE DERIVATIVE;

ALL CAUSE MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; MORTALITY;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCOPOLAMINE DERIVATIVES;

EID: 79953283384     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008532.pub2     Document Type: Review

References (42)

1. Aaron SD, Vandemheen K, Ferguson D, FitzGerald M, Maltais F, Boureau J, et al.The Canadian optimal therapy of COPD trial: Design, organization and patient recruitment. Canadian Respiratory Journal 2004; Vol. 11, issue 8:581-5.
2. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al.Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.[see comment][summary for patients in Ann Intern Med. 2007 Apr 17;146(8):I12; PMID: 17310044]. Annals of Internal Medicine 2007; Vol. 146, issue 8:545-55.
3. Kaplan A. Effects of tiotropium combined with either salmeterol or salmeterol/fluticasone in moderate to severe COPD. Primary Care Respiratory Journal 2007; Vol. 16, issue 4:258-60.
4. Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, et al.Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; Vol. 63, issue 11:962-7.
5. Roisman G. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease. A randomized trial. Revue de Pneumologie Clinique 2007; Vol. 63, issue 6:390-1.
6. Cazzola M, Ando F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, et al.A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulmonary Pharmacology and Therapeutics 2007; Vol. 20, issue 5:556-61.
7. D'Amato M, Ando F, Santus P, Ruggeri P, Di Marco F, Cazzola M. Clinical effects of adding fluticasone propionate/salmeterol (FSC) and tiotropium (TIO) in severe-to-very severe COPD [Abstract]. European Respiratory Journal 2005; Vol. 26, issue Suppl 49:Abstract No. 218.
8. Welte T, Hartman L, Polanowski T, Hernandez P. Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [Abstract]. American Thoracic Society International Conference, May 15-20, 2009, San Diego 2009:A6188 [Poster #215].
9. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al.Addition of budesonide/formoterol to tiotropium reduces the number of exacerbation days compared with tiotropium alone. Chest 2009; Vol. 136, issue 4:26S-f.
10. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al.Budesonide/formoterol added to tiotropium provides rapid improvements in lung function and ability to undertake morning activities. Chest 2009; Vol. 136, issue 4:24S-g.
11. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al.Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2009; Vol. 180, issue 8:741-50.
12. Welte T, Miravitlles M, Hernandez P, Hartman L, Polanowski T, Kessler R. Budesonide/formoterol added to tiotropium improves lung function, health status, symptoms & morning activities in COPD patients [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009:[P2005].
13. Welte T, Miravitlles M, Hernandez P, Peterson S, Polanowski T, Kessler R. Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009:[P2012].
14. Welte T, Miravitlles M, Peterson S, Polanowski T, Kessler R. Budesonide/formoterol added to tiotropium improves the management of COPD patients [Abstract]. American Thoracic Society International Conference, May 15-20, 2009, San Diego 2009:A6192 [Poster #216].
15. Ando F, Ruggeri P, Girbino G, Cazzola M. Tiotropium and salmeterol/fluticasone combination do not cause oxygen desaturation in COPD. Respiratory Medicine 2008; Vol. 102, issue 6:815-8.
16. Bateman E, Van-Dyk M, Chang A. A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD [Abstract]. European Respiratory Journal 2005; Vol. 26, issue Suppl 49:Abstract No. 851.
17. Bateman ED, van Dyk M, Sagriotis A. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: A pilot study. Pulmonary Pharmacology and Therapeutics 2008; Vol. 21, issue 1:20-5.
18. Biscione G, Crigna G, Auciello L, Pasqua F, Cazzola M. Addition of tiotropium (T) to a regular treatment with long-acting beta-agonist + inhaled corticosteroid (LABA + ICS) in patients with severe to very-severe COPD under in-patient pulmonary rehabilitation program (PRP) [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 12-16 2009:[P526].
19. Golabi P, Topaloglu N, Karakurt S, Celikel T. Effects of tiotropium and salmeterol/fluticasone combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract]. European Respiratory Journal 2006; Vol. 28, issue Suppl 50:33s [E304].
20. Hara K, Kurashima K, Tokunaga D, Ueno M, Aoyagi K, Isobe Z, et al.Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA 2007:Poster #A1.
21. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta2 agonists and corticosteroids. Respirology 2006; Vol. 11, issue 5:598-602.
22. Petroianni A, Ceccarelli D, Conti V, Graziani E, Terzano C. Evening administration of tiotropium during combination therapy reduces night symptoms in COPD patients [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4-8 2008:[E4282].
23. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; Vol. 63, issue 7:592-8.
24. Singh D, Hagan G, Cahn A, Leonard TB, Riley JH, O'Connor BJ. Individual and combined responses to salmeterol/fluticasone propionate combination (SFC) and tiotropium (Tio) shown in a COPD clinical trial [Abstract]. American Thoracic Society International Conference, May 16-21, 2008, Toronto 2008:A648[#F10].
25. Fang L, Liang X, Zhang F, Liu L, Fu W, Zhao Z, et al.Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2008;31(11):811-4.
26. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, et al.Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD006101].
27. Barr RG, Bourbeau J, Camargo CA. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2].
28. Beeh KM, Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Advances in Therapy 2010;27(3):150-9.
29. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al.Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal 2008; Vol. 31, issue 2:416-69.
30. Effing T, Monninkhof EEM, van der Valk PP, Zielhuis GGA, Walters EH, van der Palen JJ, et al.Self-management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2].
31. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com [Accessed 4th February 2011].
32. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
33. Hutchinson A, Brand C, Irving L, Roberts C, Thompson P, Campbell D. Acute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failure. Internal Medical Journal 2010; Vol. 40, issue 5:364-71. [1445-5994: (Electronic)].
34. Keene ON, Calverley PM, Jones PW, Vestbo J, Anderson JA. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal 2008; Vol. 32, issue 1:17-24. [1399-3003: (Electronic)].
35. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2].
36. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD006826].
37. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub2].
38. Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub2].
39. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration, 2008.
40. Paul Jones. St George's Respiratory Questionnaire for COPD Patients (SGRQ-C). St George's, University of London 2008.
41. Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD007891.pub2].
42. Yang IA, Fong K, Sim EHA, Black PN, Lasserson TJ. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD002991.pub2].